Pandect Bioventures
Pandect Bioventures is an early-stage life sciences investment firm that provides seed through Series A and later funding to biotech and pharmaceutical startups. The firm offers full management support, access to an onsite 40,000+ sq ft chemistry/biology incubator in South San Francisco, technical and financial research support, and advisory resources through executives-in-residence and academic/industry collaborators to advance discoveries toward patients.
Industries
Nr. of Employees
small (1-50)
Pandect Bioventures
South San Francisco, CA (incubator facility location referenced)
Portfolio
Co-invested in Series B with The Column Group and Nextech Invest; Chair of SAB is Nobel laureate William G. Kaelin Jr.
#Oncology (macrocyclic peptide discovery)
Formed as an oncology newco at the ShangPharma incubator with a UCSF co-founder; mission to deliver DDR-based oncology therapies.
#Oncology (DNA Damage Response)
Biotech spin-out from UC Berkeley; develops methods to modify therapeutic proteins to control pharmacokinetics and specificity.
#Ophthalmology (protein therapeutics)
Co-invested with The Emerson Collective; focuses on engineered B cell therapies for oncology, rare disease, regenerative medicine and autoimmune disease.
#Oncology (B cell medicines, cell-based therapeutics)
Co-invested with Arch Venture Partners; applies systems-based approaches to study and develop medicines directed to the kidney.
#Nephrology (kidney disease therapeutics)
Co-invested in Series B with The Column Group and Nextech Invest; Chair of SAB is Nobel laureate William G. Kaelin Jr.
#Oncology (macrocyclic peptide discovery)
Formed as an oncology newco at the ShangPharma incubator with a UCSF co-founder; mission to deliver DDR-based oncology therapies.
#Oncology (DNA Damage Response)
Biotech spin-out from UC Berkeley; develops methods to modify therapeutic proteins to control pharmacokinetics and specificity.
#Ophthalmology (protein therapeutics)
Co-invested with The Emerson Collective; focuses on engineered B cell therapies for oncology, rare disease, regenerative medicine and autoimmune disease.
#Oncology (B cell medicines, cell-based therapeutics)
Co-invested with Arch Venture Partners; applies systems-based approaches to study and develop medicines directed to the kidney.
#Nephrology (kidney disease therapeutics)